Lung Transplantation and the Era of the Sensitized Patient
Katherine A. Young, Hakim Azfar Ali, K. Beermann, John M. Reynolds, Laurie D. Snyder
Abstract
Long term outcomes in lung transplant are limited by the development of chronic lung allograft dysfunction (CLAD). Within the past several decades, antibody-mediated rejection (AMR) has been recognized as a risk factor for CLAD. The presence of HLA antibodies in lung transplant candidates, "sensitized patients" may predispose patients to AMR, CLAD, and higher mortality after transplant. This review will discuss issues surrounding the sensitized patient, including mechanisms of sensitization, implications within lung transplant, and management strategies.
Topics & Concepts
MedicineLung transplantationLungIntensive care medicineSensitizationDonor specific antibodiesTransplantationGraft rejectionImmunologyHuman leukocyte antigenInternal medicineAntigenTransplantation: Methods and OutcomesRenal Transplantation Outcomes and TreatmentsOrgan Transplantation Techniques and Outcomes